AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27055679 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol sodium ophthalmic solution (DQS)
Number of subjects: 17
Study 27055679 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (AT)
Number of subjects: 17
Study 27055679 — intervention group
Group type: EXPERIMENTAL
Intervention: DQS
Number of subjects: 17
Study 27055679 — intervention group
Group type: COMPARATOR
Intervention: AT
Number of subjects: 17
Study 25041069 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol+energy drink condition
Number of subjects: 75
Study 25041069 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-only condition
Number of subjects: 75
Study 22167565 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) dosing strategies
Number of subjects: 52
Study 22167565 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model for VPA
Number of subjects: 52
Study 22167565 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the pharmacokinetic model to SMA patients
Number of subjects: 52
Study 20693880 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (15 subjects)
Number of subjects: 30
Study 20693880 — intervention group
Group type: COMPARATOR
Intervention: Sitting position (15 subjects)
Number of subjects: 30
Study 20693880 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CEPs between prone and sitting positions
Number of subjects: 30
Study 18277195 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise training (ET)
Number of subjects: 101
Study 18277195 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous intervention (PCI)
Number of subjects: 101
Study 18277195 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival rates
Number of subjects: 101
Study 16466165 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiongshao Capsule (XSC)
Number of subjects: 124
Study 16466165 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 124
Study 12933954 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting (wrist splint worn at night for at least six weeks)
Number of subjects: 89
Study 10223781 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg daily)
Number of subjects: 12
Study 10223781 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily)
Number of subjects: 12
Study 10223781 — intervention group
Group type: COMPARATOR
Intervention: Control (oral contraceptives only)
Number of subjects: 12
Study 8656328 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline personality disorder diagnosis
Number of subjects: 320
Study 8656328 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcissistic personality disorder diagnosis
Number of subjects: 320
Study 2083081 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoval cream
Number of subjects: 0
Study 2083081 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone Aster à 1%
Number of subjects: 0
Study 2083081 — intervention group
Group type: COMPARATOR
Intervention: Parfenac, indomethacin 2.5%
Number of subjects: 0
Study 2083081 — intervention group
Group type: COMPARATOR
Intervention: Skinbase
Number of subjects: 0
Study 2083081 — intervention group
Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 0
Study 2083081 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorimetric parameters a* (redness) and L* (luminance)
Number of subjects: 0
Study 2083081 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepidermal water loss
Number of subjects: 0
Study 630211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, and prednisolone (combination chemotherapy)
Number of subjects: 66
Study 630211 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (single-agent chemotherapy)
Number of subjects: 66
Study 630211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (combination and single-agent chemotherapy)
Number of subjects: 66
Study 30929590 — intervention group
Group type: EXPERIMENTAL
Intervention: Art Therapy (AT) for eight weeks
Number of subjects: 20
Study 30929590 — intervention group
Group type: COMPARATOR
Intervention: Sham Art Therapy (mandala coloring group) for eight weeks
Number of subjects: 20
Study 29137028 — intervention group
Group type: EXPERIMENTAL
Intervention: CABPB with positioning posterior cord guided by nerve stimulator (group A)
Number of subjects: 80
Study 29137028 — intervention group
Group type: COMPARATOR
Intervention: CABPB guided by ultrasound (group B)
Number of subjects: 80
Study 26040317 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-aided insertion and air insufflation during withdrawal
Number of subjects: 92
Study 26040317 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation during both insertion and withdrawal
Number of subjects: 92
Study 26040317 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-aided insertion
Number of subjects: 92
Study 26040317 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 92
Study 23351071 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) therapy
Number of subjects: 36
Study 21572373 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV (2 + 1)
Number of subjects: 172
Study 21572373 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV (3 + 1)
Number of subjects: 172
Study 21572373 — intervention group
Group type: COMPARATOR
Intervention: Control (unprimed)
Number of subjects: 172
Study 18313881 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU-based treatment
Number of subjects: 855
Study 16504835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (specifics not provided)
Number of subjects: 0
Study 16504835 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c quartiles (specifics not provided)
Number of subjects: 0
Study 16504835 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables (age, duration of diabetes, insulin use, smoking history, hypertension, BMI, race, ethnicity, cholesterol levels, statin use)
Number of subjects: 0
Study 12946547 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg QD for 12 months
Number of subjects: 96
Study 12946547 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 16 mg QD for 12 months
Number of subjects: 96
Study 12946547 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and Candesartan (both groups)
Number of subjects: 96
Study 11559960 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.7 mg/kg)
Number of subjects: 16
Study 11559960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10086826 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit smoking at some point during the first year and stayed quit
Number of subjects: 5887
Study 10086826 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked intermittently during the study
Number of subjects: 5887
Study 10086826 — intervention group
Group type: COMPARATOR
Intervention: Continued to smoke throughout the study
Number of subjects: 5887
Study 10086826 — intervention group
Group type: EXPERIMENTAL
Intervention: Several attempts to quit smoking
Number of subjects: 5887
Study 10086826 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking for an interval followed by relapse to smoking
Number of subjects: 5887
Study 7994166 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental intravenous infusion of adrenaline (low, intermediate, high doses)
Number of subjects: 10
Study 7994166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 10
Study 2544291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravenous GR43175
Number of subjects: 8
Study 2544291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 19127179 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 12
Study 19127179 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of Direction Speed (CODS) with Static Stretching (SS)
Number of subjects: 12
Study 19127179 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study 429499 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sulpiride orally twice a day during the first 7 days of the puerperium
Number of subjects: 130
Study 429499 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally twice a day during the first 7 days of the puerperium
Number of subjects: 130
Study 429499 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sulpiride orally
Number of subjects: 130
Study 429499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 31827679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic resistance training with elastic bands (TG)
Number of subjects: 22
Study 31827679 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study 29136343 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD-4023 (2.5 mg)
Number of subjects: 42
Study 29136343 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD-4023 (7.5 mg)
Number of subjects: 42
Study 29136343 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD-4023 (15 mg)
Number of subjects: 42
Study 29136343 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD-4023 (all doses)
Number of subjects: 42
Study 29136343 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 42
Study 29297667 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet fixation combined with interbody fusion (Cage 'Facet Wedge')
Number of subjects: 145
Study 29297667 — intervention group
Group type: COMPARATOR
Intervention: Pedicle screw installation after open decompression and interbody fusion (control group)
Number of subjects: 145
Study 24138460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 26
Study 24138460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21809149 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC intervention communities
Number of subjects: 24
Study 21809149 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 24
Study 20079166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine-based HAART
Number of subjects: 198
Study 17488174 — intervention group
Group type: EXPERIMENTAL
Intervention: Orff-based music therapy
Number of subjects: 26
Study 17488174 — intervention group
Group type: EXPERIMENTAL
Intervention: Social work
Number of subjects: 26
Study 17488174 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 26
Study 15207890 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly for 4 weeks followed by alendronate 10 mg once daily for 4 weeks
Number of subjects: 406
Study 11920985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) with exposure-based behavior therapy
Number of subjects: 135
Study 11920985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) with nonexposure-based behavior therapy
Number of subjects: 135
Study 11920985 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 135
Study 11920985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment cue reactivity
Number of subjects: 135
Study 9760611 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule-bending ring
Number of subjects: 100
Study 9760611 — intervention group
Group type: COMPARATOR
Intervention: No capsule-bending ring (Control)
Number of subjects: 100
Study 8638858 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anesthetics (EMLA)
Number of subjects: 20
Study 8638858 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study 2655451 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 313
Study 2655451 — intervention group
Group type: COMPARATOR
Intervention: Ortho‐Novum 7/7/7
Number of subjects: 313
Study 2655451 — intervention group
Group type: COMPARATOR
Intervention: Tri‐Norinyl
Number of subjects: 313
Study 798194 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg daily)
Number of subjects: 30
Study 798194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30894208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg q2w + MTX
Number of subjects: 243
Study 30894208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w + MTX
Number of subjects: 243
Study 30894208 — intervention group
Group type: COMPARATOR
Intervention: Placebo switching to Sarilumab 150 mg q2w + MTX
Number of subjects: 243
Study 30894208 — intervention group
Group type: COMPARATOR
Intervention: Placebo switching to Sarilumab 200 mg q2w + MTX
Number of subjects: 243
Study 30894208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg
Number of subjects: 243
Study 30894208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 243
Study 30894208 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Sarilumab 150 mg
Number of subjects: 243
Study 30894208 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Sarilumab 200 mg
Number of subjects: 243
Study 28678854 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet on peri-TKA management
Number of subjects: 42
Study 28678854 — intervention group
Group type: COMPARATOR
Intervention: Standard information by the surgeon
Number of subjects: 42
Study 25752969 — intervention group
Group type: EXPERIMENTAL
Intervention: six‐day, multidimensional residential rehabilitation course
Number of subjects: 507
Study 25752969 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 507
Study 23511065 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit Now
Number of subjects: 1132
Study 23511065 — intervention group
Group type: COMPARATOR
Intervention: Quit Later
Number of subjects: 1132
Study 21751181 — intervention group
Group type: EXPERIMENTAL
Intervention: SDD (polymyxin B sulphate, tobramycin and amphotericin)
Number of subjects: 289
Study 21751181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 19428923 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine with Alhydrogel
Number of subjects: 300
Study 19428923 — intervention group
Group type: COMPARATOR
Intervention: Control (comparator)
Number of subjects: 300
Study 16728245 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cements (GIC) and resin modified glass ionomer cements (RMGIC) stored in water
Number of subjects: 0
Study 16728245 — intervention group
Group type: COMPARATOR
Intervention: Control group: GIC and RMGIC cements stored in mineral oil
Number of subjects: 0
Study 15572868 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendula officinalis
Number of subjects: 21
Study 15572868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrum muriaticum
Number of subjects: 21
Study 15572868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11060532 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 687
Study 9069476 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombotic abnormalities in patients with BIH
Number of subjects: 38
Study 9590971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac‐potassium 50 mg
Number of subjects: 109
Study 9590971 — intervention group
Group type: COMPARATOR
Intervention: Glafenine 200 mg
Number of subjects: 109
Study 3513588 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administration
Number of subjects: 250
Study 3513588 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 250
Study 29266392 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-µs pulse width
Number of subjects: 10
Study 29266392 — intervention group
Group type: EXPERIMENTAL
Intervention: 10- to 50-µs pulse widths
Number of subjects: 10
Study 28717347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil group (n=10) consuming eight 300-mg EPA-rich fish oil softgel capsules per day for 8 weeks and continued for 5 days after exercise.
Number of subjects: 21
Study 28717347 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11) consuming an equivalent number of placebo capsules.
Number of subjects: 21
Study 28717347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil group (n=10)
Number of subjects: 21
Study 26179767 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily after initial heparin treatment
Number of subjects: 1109
Study 26179767 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (control group)
Number of subjects: 1109
Study 24174925 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered global stimulation
Number of subjects: 42
Study 24174925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (of working memory)
Number of subjects: 42
Study 24174925 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 21225890 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhomogeneous static magnetic field (SMF) exposure for 30 minutes
Number of subjects: 15
Study 21225890 — intervention group
Group type: COMPARATOR
Intervention: SHAM exposure
Number of subjects: 15
Study 18318674 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid treatment (experimental group)
Number of subjects: 163
Study 18318674 — intervention group
Group type: COMPARATOR
Intervention: No antenatal corticosteroid treatment (control group)
Number of subjects: 163
Study 16898074 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium tablet formulation THYROHORMONE/Ni‐The Ltd (0.2 mg/tab)
Number of subjects: 24
Study 16898074 — intervention group
Group type: COMPARATOR
Intervention: Reference oral solution (0.3 mg/100 ml)
Number of subjects: 24
Study 16898074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 14634544 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17beta-estradiol (E(2)) 50 microg
Number of subjects: 152
Study 14634544 — intervention group
Group type: COMPARATOR
Intervention: Oral E(2) 1 mg
Number of subjects: 152
Study 14634544 — intervention group
Group type: COMPARATOR
Intervention: Oral E(2) 1 mg + gestodene 25 microg
Number of subjects: 152
Study 10847209 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated, subunit trivalent influenza vaccine (one dose: 2027 subjects, two doses: 8712 subjects)
Number of subjects: 22762
Study 10847209 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 22762
Study 8889680 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA, single oral dose of 1.5 mg/kg body weight
Number of subjects: 2
Study 1894861 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous diltiazem infusion (10 to 15 mg/h)
Number of subjects: 47
Study 1894861 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 47
Study 1894861 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diltiazem infusion (double-blind and open label)
Number of subjects: 47
Study 7201833 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (Rytmonorm), 900 mg daily
Number of subjects: 12
Study 7201833 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide, 600 mg daily
Number of subjects: 12
Study 31407311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment (weekly or every 2 weeks)
Number of subjects: 2116
Study 31407311 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2116
Study 30706864 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Projected Practical Examination (VPPE)
Number of subjects: 0
Study 30706864 — intervention group
Group type: COMPARATOR
Intervention: Conventional Practical Examination
Number of subjects: 0
Study 29171358 — intervention group
Group type: EXPERIMENTAL
Intervention: Xtampza ER (intact or crushed)
Number of subjects: 0
Study 29171358 — intervention group
Group type: EXPERIMENTAL
Intervention: OxyContin (intact or crushed)
Number of subjects: 0
Study 29171358 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) oxycodone (crushed)
Number of subjects: 0
Study 26009945 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min exercise break
Number of subjects: 96
Study 26009945 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min exercise break
Number of subjects: 96
Study 26009945 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition (10 min)
Number of subjects: 96
Study 23223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 42
Study 21471843 — intervention group
Group type: EXPERIMENTAL
Intervention: Seex retractor system (SRS)
Number of subjects: 26
Study 21471843 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cloward-style retractor (CRS)
Number of subjects: 26
Study 19417885 — intervention group
Group type: EXPERIMENTAL
Intervention: povidone‐iodine/fluoride foam (n = 30, experimental group)
Number of subjects: 61
Study 19417885 — intervention group
Group type: COMPARATOR
Intervention: placebo fluoride foam (n = 31, control group)
Number of subjects: 61
Study 17005043 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (two doses, subcutaneously administered)
Number of subjects: 147
Study 17005043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 15123024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 0
Study 11191937 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 127
Study 11191937 — intervention group
Group type: COMPARATOR
Intervention: Slow release metoprolol
Number of subjects: 127
Study 8025209 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive therapies for insulin-dependent diabetes (specific therapies not detailed)
Number of subjects: 0
Study 3789332 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Cladosporium herbarum
Number of subjects: 22
Study 3789332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30287711 — intervention group
Group type: EXPERIMENTAL
Intervention: SonicFill Bulk Fill composite
Number of subjects: 20
Study 30287711 — intervention group
Group type: COMPARATOR
Intervention: Tetric EvoCeram Bulk Fill composite
Number of subjects: 20